NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
51991-0821-28 | 51991-0821 | Everolimus | Everolimus | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | March 5, 2021 | In Use | |
51991-0821-33 | 51991-0821 | Everolimus | Everolimus | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | June 5, 2023 | In Use | |
51991-0822-28 | 51991-0822 | Everolimus | Everolimus | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | March 5, 2021 | In Use | |
51991-0822-33 | 51991-0822 | Everolimus | Everolimus | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | June 5, 2023 | In Use | |
51991-0823-28 | 51991-0823 | Everolimus | Everolimus | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | March 5, 2021 | In Use | |
51991-0823-33 | 51991-0823 | Everolimus | Everolimus | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | June 5, 2023 | In Use | |
51991-0824-28 | 51991-0824 | Everolimus | Everolimus | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct. 1, 2021 | In Use | |
51991-0824-33 | 51991-0824 | Everolimus | Everolimus | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | June 5, 2023 | In Use | |
51991-0890-33 | 51991-0890 | Erlotinib Hydrochloride | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov. 5, 2019 | April 30, 2024 | No Longer Used |
51991-0891-33 | 51991-0891 | Erlotinib Hydrochloride | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov. 5, 2019 | July 31, 2025 | In Use |
51991-0892-33 | 51991-0892 | Erlotinib Hydrochloride | Erlotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov. 5, 2019 | July 31, 2025 | In Use |
51991-0922-98 | 51991-0922 | Oxaliplatin | Oxaliplatin | 50.0 mg/10mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 22, 2017 | March 31, 2019 | No Longer Used |
51991-0923-98 | 51991-0923 | Oxaliplatin | Oxaliplatin | 100.0 mg/20mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 22, 2017 | May 31, 2019 | No Longer Used |
51991-0937-98 | 51991-0937 | Paclitaxel | Paclitaxel | 100.0 mg/16.7mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 22, 2017 | March 31, 2019 | No Longer Used |
51991-0938-98 | 51991-0938 | Paclitaxel | Paclitaxel | 300.0 mg/50mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 22, 2017 | May 31, 2019 | No Longer Used |
51991-0942-98 | 51991-0942 | Dexrazoxane Hydrochloride | Dexrazoxane | 500.0 mg/50mL | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | June 26, 2017 | Aug. 31, 2024 | In Use |
52125-0018-02 | 52125-0018 | Leucovorin Calcium | Leucovorin Calcium | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 18, 2012 | July 19, 2013 | No Longer Used |
52125-0034-02 | 52125-0034 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | July 23, 2012 | Aug. 24, 2012 | No Longer Used |
52125-0054-02 | 52125-0054 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 10, 2012 | Aug. 13, 2013 | No Longer Used |
52125-0144-01 | 52125-0144 | Methylprednisolone Sodium Succinate | Solu-Medrol | 1.0 g/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intravenous | July 18, 2012 | May 27, 2015 | No Longer Used |
52125-0150-02 | 52125-0150 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 2, 2012 | Aug. 21, 2013 | No Longer Used |
52125-0255-05 | 52125-0255 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 28, 2012 | Feb. 17, 2017 | No Longer Used |
52125-0268-02 | 52125-0268 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 6, 2016 | Dec. 6, 2016 | No Longer Used |
52125-0268-08 | 52125-0268 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 6, 2016 | Dec. 6, 2016 | No Longer Used |
52125-0268-10 | 52125-0268 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 6, 2016 | Dec. 6, 2016 | No Longer Used |
Found 10,000 results in 7 milliseconds — Export these results